‌

US Patent 12059452 Fusion proteins

Patent 12059452 was granted and assigned to Eli Lilly and Company on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Andrew Ihor Korytko0

Gregory Alan Lazar0

David Bruce Baldwin0

John Michael Beals0

Craig Duane Dickinson0

Jonathan Wesley Day0

Date of Patent

August 13, 2024

0

Patent Application Number

175779320

Date Filed

January 18, 2022

0

Patent Citations

US Patent 9018161 Protease resistant insulin analogues

0

US Patent 9260502 Protease-stabilized insulin analogues

0

US Patent 9260501 Peptide extended insulins

0

US Patent 7271149 GLP-1 fusion proteins

0

US Patent 7323543 Multiple agent diabetes therapy

0

US Patent 7452966 GLP-1 analog fusion proteins

0

US Patent 8501440 Fibrillation-resistant insulin and insulin analogues

0

US Patent 8883449 Single-chain insulin

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

Patent abstract

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12059452 Fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.